Returning for the second year, ICI (Immune Checkpoint Inhibitors) Europe 2016 focuses exclusively on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations. Incorporating insights from Bristol-Myers Squibb, Merck Sharpe and Dohme and Genentech, this meeting will deliver practical learning on what it takes to develop the next generation of ICI drugs, from pathway validation to clinical success.